1921
Volume 95, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Despite the potential benefit of primaquine in reducing transmission and radical cure of and infections, concerns over risk of hemolytic toxicity in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd) have hampered its deployment. A cross-sectional survey was conducted in 2014 to assess the G6PDd prevalence among 631 children between 6 and 59 months of age in southwestern Uganda, an area where primaquine may be a promising control measure. G6PDd prevalence was determined using three detection methods: a quantitative G6PD enzyme activity assay (Trinity Biotech G-6-PDH kit), a qualitative point-of-care test (CareStart G6PD rapid diagnostic test [RDT]), and molecular detection of the − G202A allele. Qualitative tests were compared with the gold standard quantitative assay. G6PDd prevalence was higher by RDT (8.6%) than by quantitative assay (6.8%), using a < 60% activity threshold. The RDT performed optimally at a < 60% threshold and demonstrated high sensitivity (≥ 90%) and negative predictive values (100%) across three activity thresholds (below 60%, 30%, and 40%). G202A allele frequency was 6.4%, 7.9%, and 6.8% among females, males, and overall, respectively. Notably, over half of the G202A homo-/hemizygous children expressed ≥ 60% enzyme activity. Overall, the CareStart G6PD RDT appears to be a viable screening test to accurately identify individuals with enzyme activities below 60%. The low prevalence of G6PDd across all three diagnostic modalities and absence of severe deficiency in our study suggests that there is little barrier to the use of single-dose primaquine in this region.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-0552
2016-11-02
2018-12-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/5/1094.html?itemId=/content/journals/10.4269/ajtmh.16-0552&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2015. Policy Brief on Single-Dose Primaquine as a Gametocytocide in Plasmodium falciparum Malaria. Geneva, Switzerland: Global Malaria Programme, World Health Organization. [Google Scholar]
  2. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, Baird K, Moyes C, Howes R, Ménard D, , 2013. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J 12: 1.[Crossref] [Google Scholar]
  3. De Niz M, Eziefula AC, Othieno L, Mbabazi E, Nabukeera D, Ssemmondo E, Gonahasa S, Tumwebaze P, DiLiberto D, Maiteki-Sebuguzi C, , 2013. Tools for mass screening of G6PD deficiency: validation of the WST8/1-methoxy-PMS enzymatic assay in Uganda. Malar J 12: 1.[Crossref] [Google Scholar]
  4. Ashley EA, Recht J, White NJ, , 2014. Primaquine: the risks and the benefits. Malar J 13: 1186. [Google Scholar]
  5. Luzzatto L, Nannelli C, Notaro R, , 2016. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am 30: 373393.[Crossref] [Google Scholar]
  6. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, Carter N, Cheng Q, Culpepper J, Eziefula C, , 2013. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J 12: 391.[Crossref] [Google Scholar]
  7. World Health Organization, 2015. Guidelines for the Treatment of Malaria, 3rd edition. Geneva, Switzerland: World Health Organization. [Google Scholar]
  8. Malaria Policy Advisory Committee Meeting, 2015. Point-of-Care G6PD Testing to Support Safe Use of Primaquine for the Treatment of Vivax Malaria. WHO Evidence Review Group Meeting Report. Geneva, Switzerland: WHO. [Google Scholar]
  9. Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, Luzzatto L, , 2012. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood 120: 41234133.[Crossref] [Google Scholar]
  10. Roh ME, Oyet C, Orikiriza P, Wade M, Kiwanuka GN, Mwanga-Amumpaire J, Parikh S, Boum Y, 2nd, 2016. Asymptomatic Plasmodium infections in children in low malaria transmission setting, southwestern Uganda. Emerg Infect Dis 22: 14941498.[Crossref] [Google Scholar]
  11. World Health Organization, 2008. Training for Mid-Level Managers (MLM): The Epi Coverage Survey. Immunizations, Vaccines, and Biologicals. Geneva, Switzerland: World Health Organization. [Google Scholar]
  12. Johnson MK, Clark TD, Njama-Meya D, Rosenthal PJ, Parikh S, , 2009. Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility. PLoS One 4: e7246.[Crossref] [Google Scholar]
  13. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, Nhem S, Bouchier C, Tichit M, Christophel E, Taylor WR, Baird JK, Menard D, , 2011. Performance of the CareStart G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One 6: e28357.[Crossref] [Google Scholar]
  14. World Health Organization, 1989. Glucose-6-phosphate dehydrogenase deficiency. WHO working group. Bull World Health Organ 67: 601611. [Google Scholar]
  15. De Beaudrap P, Nabasumba C, Grandesso F, Turyakira E, Schramm B, Boum Y, Etard J-F, , 2011. Heterogeneous decrease in malaria prevalence in children over a six-year period in south-western Uganda. Malar J 10: 132.[Crossref] [Google Scholar]
  16. R Core Team, 2013. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Core Team. [Google Scholar]
  17. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW, , 2015. Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res 165: 677688.[Crossref] [Google Scholar]
  18. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ, , 2012. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 3: 1237.[Crossref] [Google Scholar]
  19. Bwayo D, Kaddumukasa M, Ddungu H, Kironde F, , 2014. Prevalence of glucose-6-phosphate dehydrogenase deficiency and its association with Plasmodium falciparum infection among children in Iganga district in Uganda. BMC Res Notes 7: 372.[Crossref] [Google Scholar]
  20. Malaria Atlas Project. Population Estimates for G6PD Deficiency Table for Uganda. Available at: http://www.map.ox.ac.uk/browse-resources/g6pd/g6pdd-estimates-table/uga/. Accessed October 12, 2014. [Google Scholar]
  21. Maiga B, Dolo A, Campino S, Sepulveda N, Corran P, Rockett KA, Troye-Blomberg M, Doumbo OK, Clark TG, , 2014. Glucose-6-phosphate dehydrogenase polymorphisms and susceptibility to mild malaria in Dogon and Fulani, Mali. Malar J 13: 270.[Crossref] [Google Scholar]
  22. Shah SS, Macharia A, Makale J, Uyoga S, Kivinen K, Craik R, Hubbart C, Wellems TE, Rockett KA, Kwiatkowski DP, Williams TN, , 2014. Genetic determinants of glucose-6-phosphate dehydrogenase activity in Kenya. BMC Med Genet 15: 93.[Crossref] [Google Scholar]
  23. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, Richardson A, Teo YY, Small K, Wilson J, Jallow M, Sisay-Joof F, Pinder M, Sabeti P, Kwiatkowski DP, Rockett KA, , 2009. Allelic heterogeneity of G6PD deficiency in west Africa and severe malaria susceptibility. Eur J Hum Genet 17: 10801085.[Crossref] [Google Scholar]
  24. Adu-Gyasi D, Asante KP, Newton S, Dosoo D, Amoako S, Adjei G, Amoako N, Ankrah L, Tchum SK, Mahama E, , 2015. Evaluation of the diagnostic accuracy of CareStart G6PD deficiency rapid diagnostic test (RDT) in a malaria endemic area in Ghana, Africa. PLoS One 10: e0125796.[Crossref] [Google Scholar]
  25. Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, Oyong D, Subekti D, Rozi IE, Domingo GJ, , 2016. Assessment of point-of-care diagnostics for G6PD deficiency in malaria endemic rural eastern Indonesia. PLoS Negl Trop Dis 10: e0004457.[Crossref] [Google Scholar]
  26. von Fricken ME, Weppelmann TA, Eaton WT, Masse R, de Rochars MVB, Okech BA, , 2014. Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti. Am J Trop Med Hyg 91: 7780.[Crossref] [Google Scholar]
  27. Roca-Feltrer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A, Tor P, Chuor CM, Kheng S, Siv S, , 2014. Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia. PLoS One 9: e116143.[Crossref] [Google Scholar]
  28. Uganda Bureau of Statistics (UBOS) and ICF International, 2010. Uganda Malaria Indicator Survey 2009. Kampala, Uganda and Rockville, MD: Uganda Malaria Surveillance Project Molecular Laboratory, National Malaria Control Programme, ICF Macro. [Google Scholar]
  29. Uganda Bureau of Statistics (UBOS) and ICF International, 2015. Uganda Malaria Indicator Survey 2014–2015. Kampala, Uganda and Rockville, MD: Uganda Bureau of Statistics. [Google Scholar]
  30. Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, Gornsawun G, Kajeechiwa L, Thwin MM, Rakthinthong S, Nosten S, , 2016. Single low dose primaquine (0.25 mg/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS One 11: e0151898.[Crossref] [Google Scholar]
  31. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM, , 2007. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 7987. [Google Scholar]
  32. Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, von Seidlein L, Drakeley C, , 2012. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J 11: 360.[Crossref] [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0552
Loading
/content/journals/10.4269/ajtmh.16-0552
Loading

Data & Media loading...

  • Received : 05 Jul 2016
  • Accepted : 12 Aug 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error